Impact of escitalopram on nocturnal sleep, day-time sleepiness and performance compared to amitriptyline: A randomized, double-blind, placebo-controlled study in healthy male subjects

Pharmacopsychiatry

Volumn 43, Issue 5, 2010, Pages 166-173

  Doerr, J P ^a   Spiegelhalder, K ^a   Petzold, F ^a   Feige, B ^a   Hirscher, V ^a   Kaufmann, R ^a   Riemann, D ^a   Voderholzer, U ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Medical Psychosomatic Clinic Roseneck   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ESCITALOPRAM; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ALERTNESS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; HUMAN; MALE; MULTIPLE SLEEP LATENCY TEST; NIGHT SLEEP; PERFORMANCE MEASUREMENT SYSTEM; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SINGLE DRUG DOSE; SLEEP PARAMETERS; WORKING MEMORY; CIRCADIAN RHYTHM; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; PSYCHOMOTOR PERFORMANCE; SLEEP; SLEEP STAGE; TIME; YOUNG ADULT;

ADULT; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CIRCADIAN RHYTHM; CITALOPRAM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; HUMANS; MALE; POLYSOMNOGRAPHY; PSYCHOMOTOR PERFORMANCE; SEROTONIN UPTAKE INHIBITORS; SLEEP; SLEEP STAGES; TIME FACTORS; YOUNG ADULT;

EID: 77954867687     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0030-1249049     Document Type: Article

References (55)

1. Armitage R, Trivedi M, Rush AJ. Fluoxetine and oculomotor activity during sleep in depressed patients. Neuropsychopharmacology 1995 12 159-165
2. Atlas, scoring rules. Recording and scoring leg movements. Sleep 1991 16 749-759
3. Bakshi R. Fluoxetine and restless legs syndrome. J Neurol Sci 1996 142 151-152
4. Billiard M, Dauvilliers Y. Idiopathic hypersomnia. Sleep Med Rev 2001 5 349-358
5. Brickenkamp R. Test d2 Aufmerksamkeits-Belastungs-Test. Göttingen, Hogrefe Verlag 1994
6. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J. Clin. Psychiatry 2002 63 331-336
7. Colonna L, Reines EH, Andersen HF. A randomized,double-blind, 24-week study of escitalopram (10mg/day) versus citalopram (20mg/day) in primary care patients with major depressive patients with major depressive disorder. Curr Med Res Opin 2005 21 1659-1668
8. DeVane CL. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 1999 19 443-466
9. Dorsey CM, Lukas SE, Cunningham SL. Fluoxetine induced sleep disturbance in depressed patients. Neuropsychopharmacology 1996 14 437-442
10. Fairweather D, Kerr J, Hilton S, et al. A placebo-controlled double-blind evaluation of the pharmacodynamics of fengabine vs amitriptyline following single and multiple doses in elderly volunteers. Br J Pharmacol 1993 35 278-283
11. Feige B, Voderholzer U, Riemann D, et al. Independent sleep EEG slow-wave and spindle band dynamics associated with 4 weeks of continuous application of short-half-life hypnotics in healthy subjects. Clin Neurophysiol 1999 110 1965-1974
12. Fischer-Cornelssen K, Ferner U, Steiner H. [Multifocal psychopharmaceutic testing (Multihospital trial.)]. Arzneimittelforschung 1974 24 1706-1724
13. Gillin JC, Jernajczyk W, Valladares-Neto DC, et al. Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers. Psychopharmacology (Berl) 1994 116 433-436
14. Görtelmeyer R. Schlaffragebogen SF-A und SF-B; in Collegium Internationale Psychiatriae Scalarum (CIPS). Internationale Skalen für Psychiatrie Weinheim, Beltz 1981
15. Grimsley S, Jahn M. Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors. Clin Pharmacy 1992 11 930-957
16. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 2003 4 121-130; 12: 537549
17. Herberg K. Verkehrs- und Alltagssicherheit bei Medikation mit Citalopram. Psychopharmakotherapie 2001 18 81-88
18. Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000 15 305-318
19. Hobson JA, McCarley RW, Wyzinski PW. Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups. Science 1975 189 4196 55-58
20. Hobson JA, Pace-Schott EF, Stickgold R. Dreaming and the brain: toward a cognitive neuroscience of conscious states. Behav Brain Sci 2000 23 793-842; discussion 904-1121
21. Hornyak M, Voderholzer U, Riemann D. Treatment of depression in patients with restless legs syndrome: what is evidence-based? Sleep Med 2006 7 301-302
22. Jones DM, Allen EM, Griffiths AN, et al. Human cognitive function following binedaline (50mg and 100mg) and imipramine (75mg): results with a new battery on tests. Psychopharmacology 1986 89 198-202
23. Kiev A, Feiger A. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997 58 146-152
24. Koppitz EM. The visual aural and digit span test. New York, Grune & Stratton 1977
25. th edition. Philadelphia, Saunders 2004
26. Lader M, Melhuish A, Frcka G, et al. The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur J Clin Pharmacol 1986 31 183-190
27. Lader M, Andersen HF, Baekdal T. The effect of escitalopram on sleep problems in depressed patients. Hum Psychopharmacol 2005 20 349-354
28. Lawlor BA, Newhouse PA, Balkin TJ, et al. A preliminary study of the effects of nighttime administration of the serotonin agonist, m-CPP, on sleep architecture and behavior in healthy volunteers. Biol. Psychiatry 1991 29 281-286
29. Lepola UM, Loft H, Reines EH. Escitalopram (1020mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003 18 211-217
30. Monaca C, Boutrel B, Hen R, et al. 5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: studies in 5-HT 1A and 5-HT 1B knockout mice. Neuropsychopharmacology 2003 28 850-856
31. Murck H, Nickel T, Künzel H, et al. State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetine. Neuropsychopharmacology 2003 28 348-358
32. Nathan PJ, Sitaram G, Stough C, et al. Serotonin, noradrenaline and cognitive function: a preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor. Behav Pharmacol 2000 11 639-642
33. Oberndorfer S, Saletu-Zyhlarz G, Saletu B. Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiology 2000 42 69-81
34. Oswald I, Adam K. Effects of paroxetine on human sleep. Br J Clin Pharmacol 1986 22 97-99
35. Ramaekers JG, Muntjewerff ND, OHanlon JF. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol 1995 39 397-404
36. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992 136 873-883
37. Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Washington, Government Printing Office 1968
38. Riedel WJ, Eikmans K, Heldens A, et al. Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment. J Psychopharmacol 2005 19 12-20
39. Riemann D, Voderholzer U, Cohrs S, et al. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 2002 35 165-174
40. Roeschke J, Kögel P, Schlösser R, et al. Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects. Psychopharmacology 1997 132 44-49
41. Rosenberg C, Damsbo N, Fuglum E, et al. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. Int Clin Psychopharmacol 1994 9 41-48
42. Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2008 43 70-75
43. Saletu B. Psychopharmaka, Gehirntätigkeit und Schlaf Neurophysiologische Aspekte der Psychopharmakologie und Pharmakopsychiatrie. Bibl Psychiatr Basel, Karger Vol. 155, 1976
44. Saletu B, Frey R, Krupka M, et al. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 1991 14 439-447
45. Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997 58 348-350
46. Sharpley A, Cowen P. Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry 1995 15 85-98
47. Staner L, Kerkhofs M, Detroux D, et al. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. J. Sleep 1995 18 470-477
48. van Bemmel AL, van den Hoofdakker RH, Beersma DG, et al. Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram. Psychopharmacology (Berl) 1993 113 225-230
49. Vasar V, Appelberg B, Rimón R, et al. The effect of fluoxetine on sleep: a longitudinal, double-blind polysomnographic study of healthy volunteers. Int Clin Psychopharmacol 1994 9 203-206
50. Wade A, Lemming OM, Hedegaard KB. Escitalopram 10mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002 17 95-102
51. Wilson SJ, Bailey JE, Alford C, et al. Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers. J Psychopharmacol 2000 14 378-386
52. Wilson SJ, Bailey JE, Rich AS, et al. Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram. Eur Neuropsychopharmacol 2004 14 367-372
53. Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005 66 436-443
54. Yang C, White DP, Winkelman JW. Antidepressants and periodic leg movements of sleep. Biol. Psychiatry 2005 15; 58 6 510-514
55. Zimmermann P, Fimm B. Testbatterie zur Erfassung von Aufmerksamkeitsstörungen. Version 1.02. Freiburg Psytest 1993